GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
The details you provide on this page will not be used to send unsolicited email ... approval of the drug and WHO pre-qualification. The drug has been approved in Europe and the US as a treatment for ...
Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for ...
From an anal PrEP douche to the first women-controlled HIV prevention product, here's all the new HIV prevention products ...
Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Medpage Today on MSN1d
Another Stab at Disease-Modifying OA Drug Hits Home in Early StudyPatients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in ...
MONTREAL - Theratechnologies (NASDAQ:THTX) Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company, has revealed details from a study focusing on the treatment outcomes for heavily treatment ...
Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...
The AIDS Society of India (ASI) has called on the government to swiftly integrate HIV self-testing and pre-exposure ...
It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback